{"filings":[{"id":748079,"accession_number":"0001193125-26-248525","cik":1227636,"company_name":"Neuronetics, Inc.","ticker":"STIM","form_type":"8-K","filed_at":"2026-05-29T20:45:06+00:00","items":["5.07"],"status":"ready","headline":"Neuronetics stockholders elect all seven director nominees, approve 2026 equity plan at annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All seven director nominees elected; votes for ranged from 28.5M (Cucuz) to 34.5M (Reuvers); broker non-votes 14.66M.","KPMG ratified as auditor for FY2026 with 47.2M for, 6.9M against.","Non-binding say-on-pay advisory passed with 29.1M for, 11.5M against.","2026 Equity Incentive Plan approved with 23.8M for, 16.7M against.","55.95M shares represented (~80.4% of outstanding) at the May 28, 2026 meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.15,"market_cap_usd":98118863.87704918,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":591398,"accession_number":"0001193125-26-235481","cik":1227636,"company_name":"Neuronetics, Inc.","ticker":"STIM","form_type":"8-K","filed_at":"2026-05-22T11:30:06+00:00","items":["5.02","9.01"],"status":"ready","headline":"Neuronetics amends consulting agreement with interim PAO Brown to $26k/month until full-time roles filled","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Francis X. Brown III continues as Interim Principal Financial and Accounting Officer under amended agreement dated May 18, 2026.","Compensation changed from fixed $25,000 fee to ongoing $26,000 monthly rate.","Agreement ends when Neuronetics hires a full-time controller and principal financial and accounting officer.","Brown provides controller functions and service as interim PAO; non-compete covers TMS therapy and Greenbrook treatment modalities.","Prior interim PAO agreement terminated on May 5, 2026 after filing Q1 2026 Form 10-Q."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":98118863.87704918,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":91761,"accession_number":"0001193125-26-205117","cik":1227636,"company_name":"Neuronetics, Inc.","ticker":"STIM","form_type":"8-K","filed_at":"2026-05-05T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Neuronetics Q1 revenue $34.5M (+8% YoY); net loss improves; maintains FY2026 outlook","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $34.5M (+8% YoY); U.S. clinic revenue $21.5M (+15%) on Greenbrook acquisition and SPRAVATO expansion.","Net loss $(10.8M) ($0.16/shr) vs $(12.7M) loss a year ago; operating expenses down 6% to $25.1M.","Cash $19.0M (incl. $5.8M restricted); made $5M debt principal payment in March to reduce debt.","Optum/UHC/UBH expanded TMS policy to allow nurse practitioners to order/administer NeuroStar, covering 34.8M lives across 26 states.","FY2026 guidance: revenue $160-166M, gross margin 47-49%, op ex $100-105M, cash from ops negative $13-17M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.16,"consensus_revenue_estimate":null,"consensus_revenue_actual":34454000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":98118863.87704918,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":91760,"accession_number":"0001193125-26-143876","cik":1227636,"company_name":"Neuronetics, Inc.","ticker":"STIM","form_type":"8-K","filed_at":"2026-04-06T23:59:59+00:00","items":["1.01","2.05","5.02","7.01","9.01"],"status":"ready","headline":"Neuronetics announces CFO resignation, 5% workforce reduction, and former CEO consulting deal","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Former CEO Keith J. Sullivan enters consulting agreement with release; will vest in equity through March 2027; no additional compensation.","CFO Steven E. Pfanstiel resigns effective May 1, 2026; company launches search for successor; no dispute.","Workforce reduction impacting up to 5% of employees; expects $0.2M restructuring charge in Q2 2026.","Annualized cost savings of $2.5M to $3.0M expected, primarily starting in Q3 2026.","Reaffirms FY2026 financial guidance provided during Q4 2025 earnings call on March 17, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":98118863.87704918,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":102069,"accession_number":"0001193125-26-109403","cik":1227636,"company_name":"Neuronetics, Inc.","ticker":"STIM","form_type":"8-K","filed_at":"2026-03-17T23:59:59+00:00","items":["2.02","5.02","7.01","9.01"],"status":"ready","headline":"Neuronetics appoints new CEO Dan Reuvers; Q4 revenue $41.8M, net loss $7.2M; FY26 guidance $160-166M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Dan Reuvers appointed President and CEO effective March 23, 2026; base salary $730k, 1.5M RSU grant.","Q4 2025 revenue $41.8M (+86% YoY); net loss $(7.2)M ($(0.10) EPS).","FY2025 revenue $149.2M (+99% YoY); net loss $(39.1)M ($(0.59) EPS).","FY2026 guidance: revenue $160-166M, gross margin 47-49%, operating cash flow $(13)-(17)M.","Debt amended with Perceptive: $5M principal payment in March 2026; covenant adjustments."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":98118863.87704918,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":102068,"accession_number":"0001193125-26-085509","cik":1227636,"company_name":"Neuronetics, Inc.","ticker":"STIM","form_type":"8-K","filed_at":"2026-03-02T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Neuronetics amends registration rights with Madryn; commits to file shelf within 5 days after 2025 10-K","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Second Amendment to Registration Rights Agreement executed March 2, 2026.","If Shelf Notice received, Neuronetics must file resale registration statement within 5 business days after filing its 2025 10-K.","Madryn agrees to vote all shares in line with board recommendation on director elections, auditor, say-on-pay, and new equity plan at 2026 annual meeting.","Madryn also agrees not to submit shareholder proposals for two years."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":98118863.87704918,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":102067,"accession_number":"0001193125-26-071892","cik":1227636,"company_name":"Neuronetics, Inc.","ticker":"STIM","form_type":"8-K","filed_at":"2026-02-25T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Neuronetics approves $649K in annual cash incentives for CEO, CFO, and CLO","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["CEO Keith J. Sullivan receives $412,775.95 annual cash incentive award.","CFO Steven E. Pfanstiel receives $73,216.44; CLO W. Andrew Macan receives $163,383.75.","Awards approved Feb 23, 2026 by Compensation Committee and Board; payable on or about March 13, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":98118863.87704918,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":102066,"accession_number":"0001193125-26-044912","cik":1227636,"company_name":"Neuronetics, Inc.","ticker":"STIM","form_type":"8-K","filed_at":"2026-02-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Neuronetics reports preliminary Q4 2025 revenue $41.8M, up 23% pro forma; positive operating cash flow","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $41.8M, 23% YoY pro forma growth; NeuroStar revenue $18.3M (+9% pro forma).","Full year 2025 revenue $149.2M, 15% pro forma growth; clinic revenue $87.0M (+28% pro forma).","Q4 operating cash flow positive $0.9M; total cash $34.1M at year-end.","49 NeuroStar systems shipped in Q4.","Final Q4 results to be released March 17, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.59,"consensus_revenue_estimate":null,"consensus_revenue_actual":149157000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":98118863.87704918,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":102065,"accession_number":"0001193125-26-018674","cik":1227636,"company_name":"Neuronetics, Inc.","ticker":"STIM","form_type":"8-K","filed_at":"2026-01-22T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Neuronetics enters Amendment No. 4 to Perceptive credit facility, modifying subsidiary guarantor requirements","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Amendment introduces 'Immaterial Subsidiary' definition: assets/revenue ≤ $5M each, aggregate ≤ $10M.","Subsidiaries exceeding thresholds must become Guarantors with first-priority liens within 10 business days.","Controlled account requirements modified to exclude accounts under $300K each, $1M aggregate.","Borrower must cause specified subsidiaries to become Obligors by Jan 30, 2026, and deliver control agreements by Feb 13, 2026.","No other amendments; existing credit agreement remains in full force."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":98118863.87704918,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":102064,"accession_number":"0001193125-26-004728","cik":1227636,"company_name":"Neuronetics, Inc.","ticker":"STIM","form_type":"8-K","filed_at":"2026-01-06T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Neuronetics grants $240K cash + 170K RSUs to CFO, $231.75K cash + 164K RSUs to GC","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Cash award of $240,000 and 170,212 RSUs granted to CFO Steven E. Pfanstiel.","Cash award of $231,750 and 164,361 RSUs granted to General Counsel W. Andrew Macan.","Awards vest on earlier of June 30, 2027 or termination without cause."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":98118863.87704918,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118412,"accession_number":"0001193125-25-263541","cik":1227636,"company_name":"Neuronetics, Inc.","ticker":"STIM","form_type":"8-K","filed_at":"2025-11-04T23:59:59+00:00","items":["2.02","5.02","7.01","9.01"],"status":"ready","headline":"Neuronetics Q3 revenue $37.3M (+11% adj pro forma); FY guidance cut; CEO Sullivan to retire June 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $37.3M (+101% YoY, +11% adjusted pro forma); Greenbrook clinic revenue $21.8M (+25% adj pro forma).","Net loss $(9.4)M ($0.13/shr) vs $(13.3)M ($0.44/shr) last year; gross margin 45.9% (down from 75.6% on business mix).","Lowers FY2025 revenue guidance to $147-150M (from $149-155M); gross margin 47-49% (from 48-50%).","CEO Keith Sullivan to retire June 30, 2026; board commenced search; no dispute with management.","Ended Q3 with $34.5M cash; used $0.8M in ops; secured additional $10M Perceptive debt; raised $7.8M net via ATM."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.49,"consensus_revenue_estimate":null,"consensus_revenue_actual":107380000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":98118863.87704918,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134846,"accession_number":"0001193125-25-173033","cik":1227636,"company_name":"Neuronetics, Inc.","ticker":"STIM","form_type":"8-K","filed_at":"2025-08-05T23:59:59+00:00","items":["1.01","2.02","7.01","9.01"],"status":"ready","headline":"Neuronetics Q2 rev $38.1M (+132% YoY); secures $10M additional debt; lowers liquidity requirement to $2M through Sep'26","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Q2 2025 revenue $38.1M, up 132% YoY; adjusted pro forma growth 18%; net loss $(9.8)M ($0.15 loss per share).","Record Greenbrook clinic revenue $23.0M; U.S. treatment session revenue $10.8M (pro forma +13%); shipped 41 NeuroStar systems.","Received $10M Tranche 2A loan from Perceptive on Aug 1, 2025; minimum liquidity lowered to $2M through Sep 2026; still eligible for $5M more.","Appointed Steven Pfanstiel as CFO effective July 15, 2025; succeeded Stephen Furlong.","Guidance: Q3 rev $37-39M, FY rev $149-155M; FY operating expenses raised to $100-105M; cash flow positive expected in Q4 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":98118863.87704918,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134845,"accession_number":"0001193125-25-159026","cik":1227636,"company_name":"Neuronetics, Inc.","ticker":"STIM","form_type":"8-K","filed_at":"2025-07-15T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Neuronetics appoints Steven Pfanstiel as CFO; reaffirms Q2 & FY2025 guidance","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Pfanstiel named CFO effective July 15, replacing retiring Steve Furlong (through March 2026).","Pfanstiel previously CFO/COO of Marinus Pharmaceuticals; 20+ years medical device/pharma experience.","Inducement grant of 400,000 RSUs vesting over 3-4 years; base salary $480k, 50% target bonus.","Reaffirms Q2 and full-year 2025 guidance; targets positive cash flow in Q3 2025.","Outgoing CFO Furlong remains as Senior Advisor to CEO through end of March 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":98118863.87704918,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151775,"accession_number":"0001193125-25-128678","cik":1227636,"company_name":"Neuronetics, Inc.","ticker":"STIM","form_type":"8-K","filed_at":"2025-05-28T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Neuronetics shareholders reject supermajority elimination; all directors elected","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All 7 director nominees elected with >36.7M votes each; broker non-votes of ~15.8M.","Ratification of KPMG as auditor passed with 53.5M for (99.98% of votes cast).","Advisory say-on-pay approved with 36.97M for, 708K against.","Proposal to eliminate supermajority voting failed: 11.7M for, 25.6M against, 16.0M broker non-votes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":98118863.87704918,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151774,"accession_number":"0001193125-25-113283","cik":1227636,"company_name":"Neuronetics, Inc.","ticker":"STIM","form_type":"8-K","filed_at":"2025-05-06T23:59:59+00:00","items":["2.02","5.02","7.01","9.01"],"status":"ready","headline":"Neuronetics Q1 revenue $32M (+84% YoY); narrows FY guidance; CFO to retire March 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 revenue $32.0M, up 84% YoY driven by Greenbrook acquisition; net loss $(12.7)M vs $(7.9)M","U.S. clinic revenue $18.7M (post-Greenbrook); NeuroStar system revenue $2.8M (-14%)","CFO Steve Furlong to retire March 31, 2026; search for successor underway","Full-year 2025 revenue guidance narrowed to $149M-$155M (prev $145M-$155M)","Cash $20.2M; expects Q3 2025 cash flow positive; Q2 cash usage <$5M"],"consensus_eps_estimate":null,"consensus_eps_actual":-0.21,"consensus_revenue_estimate":null,"consensus_revenue_actual":31975000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":98118863.87704918,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170630,"accession_number":"0001558370-25-003832","cik":1227636,"company_name":"Neuronetics, Inc.","ticker":"STIM","form_type":"8-K/A","filed_at":"2025-03-27T23:59:59+00:00","items":["2.02","7.01","2.01","9.01"],"status":"ready","headline":"Neuronetics revises Q4 2024 results: net loss up to $12.7M from $12.2M on Greenbrook acquisition accounting adjustments","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2024 net loss revised to $(12.7)M ($(0.34)/share) from $(12.2)M ($(0.33)/share) initially reported.","Q4 adjusted EBITDA now $(0.4)M, down from $0.1M reported on March 4, 2025.","Full-year 2024 net loss revised to $(43.7)M ($(1.38)/share) from $(43.2)M ($(1.37)/share).","Full-year adjusted EBITDA revised to $(21.8)M from $(21.3)M previously.","Revision caused by $0.6M reduction in assumed Greenbrook bonus accrual under purchase accounting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":98118863.87704918,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170634,"accession_number":"0001193125-25-044817","cik":1227636,"company_name":"Neuronetics, Inc.","ticker":"STIM","form_type":"8-K","filed_at":"2025-03-04T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Neuronetics Q4 rev $22.5M (+11% YoY); closes Greenbrook TMS, guides FY25 rev $145-155M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2024 total revenue $22.5M (+11% YoY); U.S. treatment session revenue $12.9M; clinic revenue from Greenbrook $4.4M.","Net loss Q4 $(12.2)M or $(0.33) per share vs $(5.4)M or $(0.19) in Q4 2023.","Acquired Greenbrook TMS on Dec 9, 2024 adding 95 U.S. clinics; secured $10M from Perceptive Advisors at close.","Realized over $21M of $22M targeted annualized cost synergies from Greenbrook integration.","Completed $18.9M secondary offering in Feb 2025; guides FY25 rev $145-155M and Q3 2025 cash flow positive."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":98118863.87704918,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170633,"accession_number":"0001193125-25-044451","cik":1227636,"company_name":"Neuronetics, Inc.","ticker":"STIM","form_type":"8-K","filed_at":"2025-03-04T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Neuronetics approves 2025 annual cash incentive awards for CEO, CFO, and GC","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["CEO Keith J. Sullivan receives $169,260 annual cash incentive award approved by Board on Feb 24.","CFO Stephen Furlong receives $100,794; GC W. Andrew Macan receives $97,313.","Awards payable on or about March 6, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":98118863.87704918,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170632,"accession_number":"0001193125-25-022833","cik":1227636,"company_name":"Neuronetics, Inc.","ticker":"STIM","form_type":"8-K","filed_at":"2025-02-10T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Neuronetics prices $18M public offering of 8M shares at $2.25/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds ~$18M from 8M shares (plus underwriter option 1.2M shares exercised).","Net proceeds expected ~$16.4M (or ~$18.9M including option).","Canaccord Genuity LLC sole bookrunner; offering closes Feb 10, 2025.","Proceeds to be used for general corporate purposes including sales, R&D, and acquisitions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":98118863.87704918,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170629,"accession_number":"0001193125-25-021800","cik":1227636,"company_name":"Neuronetics, Inc.","ticker":"STIM","form_type":"8-K/A","filed_at":"2025-02-06T23:59:59+00:00","items":["9.01"],"status":"ready","headline":"Neuronetics files Greenbrook FY22-23 audited, Q3 2024 unaudited, and pro forma financials","summary_kind":"llm","event_type":"m_and_a","confidence":"medium","bullets":["Acquisition of all Greenbrook common shares closed December 9, 2024.","Audited Greenbrook financials for FY22 and FY23 filed as Exhibit 99.1.","Unaudited Greenbrook financials for nine months ended Sep 30, 2024 filed as Exhibit 99.2.","Pro forma combined balance sheet as of Sep 30, 2024 and combined statements of operations for 2023 and nine months 2024 filed as Exhibit 99.3."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":98118863.87704918,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170631,"accession_number":"0001193125-25-005006","cik":1227636,"company_name":"Neuronetics, Inc.","ticker":"STIM","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Neuronetics reports preliminary Q4 revenue $22.1M, FY2024 $74.5M; issues 2025 guidance with 12-19% growth","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Preliminary Q4 2024 revenue $22.1M; full-year 2024 revenue $74.5M (combined with Greenbrook from Dec 9).","Closed acquisition of Greenbrook TMS Dec 9, 2024; expects over $22M annualized cost synergies.","FY2025 revenue guidance $145M-$155M, pro forma growth 12-19%; gross margin ~55%.","Expects cash flow breakeven in Q3 2025; reduced cash burn in H1 2025.","Launched Better Me Provider program with over 350 sites; FDA clearance for adolescent MDD expanded TAM by 35%."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.38,"consensus_revenue_estimate":null,"consensus_revenue_actual":74890000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":98118863.87704918,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":187616,"accession_number":"0001193125-24-274383","cik":1227636,"company_name":"Neuronetics, Inc.","ticker":"STIM","form_type":"8-K","filed_at":"2024-12-10T23:59:59+00:00","items":["1.01","2.01","3.02","5.02","5.03","8.01","9.01"],"status":"ready","headline":"Neuronetics closes Greenbrook TMS acquisition; adds 2 directors; secures $10M loan amendment.","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Acquisition closed Dec 9; exchange ratio 0.01021 Neuronetics share per Greenbrook share; Greenbrook to delist from OTCQB.","Madryn converted ~2.06B Greenbrook Shares from credit agreement and ~253M from interim funding, receiving Neuronetics shares at exchange ratio.","Board expanded to 7; appointed Sasha Cucuz (Greybrook CEO) and Dr. Avinash Amin (Madryn managing partner).","Credit agreement with Perceptive amended to allow $10M Tranche 3 loan for combined operations and new revenue covenants; warrant for 600k shares issued.","Combined company to operate as Neuronetics (STIM); integration targeting cost synergies and profitable growth."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":98118863.87704918,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":187615,"accession_number":"0001193125-24-256238","cik":1227636,"company_name":"Neuronetics, Inc.","ticker":"STIM","form_type":"8-K","filed_at":"2024-11-13T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Neuronetics regains Nasdaq minimum bid price compliance; delisting risk resolved","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified Neuronetics on Nov 12 that it regained compliance with the $1.00 minimum bid price rule.","Compliance achieved by maintaining closing bid price ≥$1.00 for 10 consecutive business days through Nov 11.","Previous non-compliance was disclosed on Oct 4, 2024; matter is now closed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":98118863.87704918,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":187607,"accession_number":"0001193125-24-256576","cik":1227636,"company_name":"Neuronetics, Inc.","ticker":"STIM","form_type":"8-K/A","filed_at":"2024-11-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Neuronetics Q3 rev $18.5M (+4% YoY); cash flow breakeven shifted to Q3 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 revenue $18.5M (+4% vs Q3 2023); U.S. system revenue $4.1M (+14%), treatment session revenue $13.3M (+2%).","Net loss $(13.3)M ($(0.44)/share) vs $(9.4)M ($(0.33)/share) in Q3 2023; EBITDA $(11.6)M.","Shareholders approved all-stock Greenbrook TMS acquisition; expects cash flow breakeven by Q3 2025 (corrected from Q2).","Q4 2024 standalone revenue guidance $19M-$20M; full-year 2024 guidance $71M-$72M.","188,000 patients treated globally; NeuroStar adolescent TMS data showed 78% response rate at AACAP."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.04,"consensus_revenue_estimate":null,"consensus_revenue_actual":52397000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":98118863.87704918,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":187614,"accession_number":"0001193125-24-255114","cik":1227636,"company_name":"Neuronetics, Inc.","ticker":"STIM","form_type":"8-K","filed_at":"2024-11-12T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Neuronetics shareholders approve all proposals for Greenbrook acquisition","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Charter amendment to increase authorized shares to 250M approved with 16.66M for, 7.33M against.","Share issuance to Greenbrook shareholders approved with 11.96M for, 5.73M against (67.56% of votes cast).","Equity plan amendment adding 3.5M shares approved narrowly with 53.56% of votes cast.","Adjournment proposal approved with 16.12M for, 7.56M against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":98118863.87704918,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":187613,"accession_number":"0001193125-24-255111","cik":1227636,"company_name":"Neuronetics, Inc.","ticker":"STIM","form_type":"8-K","filed_at":"2024-11-12T23:59:59+00:00","items":["2.05","9.01"],"status":"ready","headline":"Neuronetics reduces workforce by 10%, expects >$3.5M annual cash savings","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Workforce reduction of approximately 10% to sharpen focus on growth.","Anticipated post-reorganization annualized cash savings of more than $3.5 million.","Expected severance and related costs of approximately $0.4 million.","Reorganization intended to improve operational efficiency and commercial strategy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":98118863.87704918,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":187612,"accession_number":"0001193125-24-255110","cik":1227636,"company_name":"Neuronetics, Inc.","ticker":"STIM","form_type":"8-K","filed_at":"2024-11-12T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Neuronetics Q3 revenue up 4% to $18.5M; net loss widens to $13.3M; stockholders approve Greenbrook deal","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $18.5M (+4% YoY); U.S. system revenue $4.1M (+14%) on 48 units; treatment session revenue $13.3M (+2%)","Gross margin improved to 75.6% from 65.8% due to product mix and absence of prior-year manufacturing costs","Net loss widened to $13.3M ($0.44/sh) from $9.4M ($0.33/sh) in Q3 2023; EBITDA -$11.6M vs -$7.7M; cash $20.9M","Stockholders approved Greenbrook acquisition Nov 8; court hearing Nov 15; expect cash flow breakeven by Q2 2025","Full-year 2024 revenue guidance narrowed to $71-72M; Q4 2024 revenue guidance $19-20M"],"consensus_eps_estimate":null,"consensus_eps_actual":-1.04,"consensus_revenue_estimate":null,"consensus_revenue_actual":52397000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":98118863.87704918,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":187611,"accession_number":"0001193125-24-249941","cik":1227636,"company_name":"Neuronetics, Inc.","ticker":"STIM","form_type":"8-K","filed_at":"2024-11-01T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Neuronetics extends Madryn's demand registration period from 180 to 365 days post-merger close","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amends Registration Rights Agreement with Madryn Asset Management LP.","Demand Registration Period for Consideration Shares extended to 365 days from close of Greenbrook TMS arrangement.","Previously, period was 180 days; amendment effective November 1, 2024.","Change is a limited procedural adjustment to existing merger-related agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":98118863.87704918,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":187610,"accession_number":"0001193125-24-233128","cik":1227636,"company_name":"Neuronetics, Inc.","ticker":"STIM","form_type":"8-K","filed_at":"2024-10-04T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Neuronetics gets Nasdaq deficiency notice for bid price below $1.00; 180-day cure period","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq letter on Oct 3, 2024; stock closed below $1.00 for 30 consecutive business days.","Must regain compliance by April 1, 2025; cure by closing at $1.00+ for 10 consecutive business days.","If not cured, may transfer to Nasdaq Capital Market for second 180-day compliance period.","Company considering available options, including a reverse stock split, to regain compliance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":98118863.87704918,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":187609,"accession_number":"0001193125-24-232682","cik":1227636,"company_name":"Neuronetics, Inc.","ticker":"STIM","form_type":"8-K","filed_at":"2024-10-04T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Neuronetics receives interim court order for Greenbrook acquisition; shareholder meetings set for Nov 8","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Ontario court grants interim order for statutory plan of arrangement; Neuronetics to acquire Greenbrook in all-stock transaction.","Each Greenbrook share exchanges for 0.01149 Neuronetics shares; combined ownership ~57% Neuronetics, 43% Greenbrook.","Both special shareholder meetings scheduled for November 8, 2024, in virtual-only format.","Greenbrook Board (unanimously) and Neuronetics Board recommend voting in favor of the arrangement.","Approval requires 2/3 Greenbrook vote, majority excluding Madryn, and majority Neuronetics vote."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":98118863.87704918,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":187608,"accession_number":"0001193125-24-231186","cik":1227636,"company_name":"Neuronetics, Inc.","ticker":"STIM","form_type":"8-K","filed_at":"2024-10-02T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Neuronetics files investor presentation highlighting benefits of Greenbrook acquisition","summary_kind":"llm","event_type":"m_and_a","confidence":"medium","bullets":["Presentation distributed on Oct 2, 2024 detailing strategic rationale and financial benefits of buying Greenbrook TMS Inc.","Includes forward-looking projections on combined growth, profitability, and synergy opportunities.","Deal requires stockholder approval; preliminary proxy statement filed Sept 17, 2024.","Management cites federal and state regulatory tailwinds as key support for the transaction.","Filing contains customary safe harbor and risk factor disclosures regarding the pending arrangement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":98118863.87704918,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":204102,"accession_number":"0001193125-24-201350","cik":1227636,"company_name":"Neuronetics, Inc.","ticker":"STIM","form_type":"8-K","filed_at":"2024-08-15T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Neuronetics hosts fireside chat on proposed acquisition of Greenbrook TMS","summary_kind":"llm","event_type":"m_and_a","confidence":"medium","bullets":["Neuronetics CEO Keith Sullivan and Greenbrook CEO Bill Leonard discuss deal impact on NeuroStar practices.","Proposed combination of Neuronetics and Greenbrook TMS described; no financial terms or timeline disclosed.","Filing includes forward-looking statements and risk factors related to the proposed arrangement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":98118863.87704918,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":204101,"accession_number":"0001193125-24-199931","cik":1227636,"company_name":"Neuronetics, Inc.","ticker":"STIM","form_type":"8-K","filed_at":"2024-08-14T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Neuronetics announces FDA clearance for NeuroStar add-on therapy for ages 15 and older","summary_kind":"llm","event_type":"regulatory","confidence":"medium","bullets":["FDA cleared NeuroStar Advanced Therapy System as an add-on treatment for patients aged 15 and older.","Management targets cash flow break-even in Q4 2024 and on a full-year basis in 2025.","Proposed combination with Greenbrook TMS Inc. remains ongoing; stockholder approval pending.","Company presenting at William Blair 44th Annual Growth Stock Conference on August 14, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":98118863.87704918,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":204100,"accession_number":"0001193125-24-199454","cik":1227636,"company_name":"Neuronetics, Inc.","ticker":"STIM","form_type":"8-K","filed_at":"2024-08-13T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Neuronetics to acquire Greenbrook TMS in all-stock deal; combined company to be 57% owned by Neuronetics shareholders","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Neuronetics issues ~25.3M shares to Greenbrook holders; existing Neuronetics shareholders own 57% of combined entity.","Greenbrook shareholders get 43% of combined co.; Madryn (key Greenbrook holder) gets 2 board seats on 7-member board.","Transaction expected to close by Dec 10, 2024, subject to shareholder & court approvals, Nasdaq review, and debt conversion conditions.","Termination fee of $1.9M payable by either party under certain circumstances.","Neuronetics will rely on Section 3(a)(10) exemption for share issuance; registration rights granted to Madryn."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":98118863.87704918,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":204099,"accession_number":"0001193125-24-198986","cik":1227636,"company_name":"Neuronetics, Inc.","ticker":"STIM","form_type":"8-K","filed_at":"2024-08-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Neuronetics reports Q2 2024 financial results and proposed combination with Greenbrook TMS","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Neuronetics issued a press release on August 12, 2024, announcing unaudited financial results for the three and six months ended June 30, 2024.","The company also announced a proposed combination with Greenbrook TMS Inc., referred to as the Proposed Arrangement.","A conference call was held on August 12, 2024, to discuss the quarterly results and the Proposed Arrangement.","The filing includes a transcript of the conference call as Exhibit 99.1, incorporated by reference."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.59,"consensus_revenue_estimate":null,"consensus_revenue_actual":33867000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":98118863.87704918,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":204098,"accession_number":"0001193125-24-198417","cik":1227636,"company_name":"Neuronetics, Inc.","ticker":"STIM","form_type":"8-K","filed_at":"2024-08-12T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Neuronetics to acquire Greenbrook TMS in all-stock deal; Q2 revenue down 7%, net loss widens","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Q2 revenue $16.5M (-7% YoY); net loss $(9.8)M ($0.33) vs $(4.9)M ($0.17) prior year.","Acquisition of Greenbrook TMS in all-stock deal; pro forma 2023 revenue ~$145M, double stand-alone.","Expects at least $15M annualized cost synergies; Adjusted EBITDA positive in FY2025, cash flow positive.","Secured $50M debt facility with Perceptive Advisors (up to $90M); repaid SLR Capital loan.","Q3 guidance revenue $18.5M-$19.5M; FY2024 revenue $78M-$80M, opex $78M-$80M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":98118863.87704918,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":204097,"accession_number":"0001193125-24-188309","cik":1227636,"company_name":"Neuronetics, Inc.","ticker":"STIM","form_type":"8-K","filed_at":"2024-07-30T23:59:59+00:00","items":["1.01","1.02","2.03","9.01"],"status":"ready","headline":"Neuronetics enters up to $90M credit facility with Perceptive, replaces SLR debt","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Borrowed $50M initial tranche, used $64.6M to repay SLR Investment Corp. loan in full including fees and interest.","Facility includes two additional tranches: $15M available by Dec 31, 2025 upon revenue milestone, and $25M by June 30, 2026 with lender consent.","Issued warrants to Perceptive for up to 1,462,500 shares; initial warrant exercisable into 1,125,000 shares at VWAP-based price.","Interest rate is 7.00% plus the greater of 4.50% or 1-month SOFR; maturity July 25, 2029."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":98118863.87704918,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":220812,"accession_number":"0001193125-24-155511","cik":1227636,"company_name":"Neuronetics, Inc.","ticker":"STIM","form_type":"8-K","filed_at":"2024-06-06T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Neuronetics presents financial and operational outlook at William Blair conference","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Presentation provides FY2024 outlook metrics but specific numbers not extracted.","Outlook includes revenue, expenses, growth expectations; risks detailed in SEC filings.","Company expects cash flow break-even in Q4 2024 and full-year 2025 goal mentioned.","No update on prior guidance; presentation is furnished, not filed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":98118863.87704918,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":220811,"accession_number":"0001193125-24-153005","cik":1227636,"company_name":"Neuronetics, Inc.","ticker":"STIM","form_type":"8-K","filed_at":"2024-06-03T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Neuronetics annual meeting results: all director nominees elected, advisory votes pass","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All five director nominees elected; For votes ranged from 15.3M to 17.7M; broker non-votes of 5.4M.","KPMG ratified as independent auditor for 2024 with 20,820,189 For, 2,340,133 Against, 442 Abstain.","Say-on-pay approved with 12,125,947 For (68.5% of votes cast), 5,576,257 Against.","Stockholders selected a 1-year frequency for future advisory votes on exec compensation (17,435,845 For 1 year)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":98118863.87704918,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":220810,"accession_number":"0001558370-24-006909","cik":1227636,"company_name":"Neuronetics, Inc.","ticker":"STIM","form_type":"8-K","filed_at":"2024-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Neuronetics Q1 revenue $17.4M (+12% YoY); FDA clearance for adolescent MDD expands TAM by ~35%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $17.4M (+12% YoY); U.S. treatment session revenue $13.0M (+22% YoY) driven by higher utilization.","Net loss $(7.9)M ($0.27/share) improved from $(10.5)M ($0.38/share) in Q1 2023; EBITDA $(6.3)M vs $(9.4)M.","NeuroStar received FDA clearance as first-line adjunct TMS for adolescents (15-21) with MDD; total addressable market increased ~35%.","Shipped 41 systems (vs 49 in Q1 2023); system revenue down 14% due to customer credit challenges and Change Health cyberattack.","Q2 2024 revenue guidance $18-19M; FY2024 revenue $78-80M; operating expenses $80-84M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.27,"consensus_revenue_estimate":null,"consensus_revenue_actual":17417000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":98118863.87704918,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":220809,"accession_number":"0001558370-24-006907","cik":1227636,"company_name":"Neuronetics, Inc.","ticker":"STIM","form_type":"8-K","filed_at":"2024-05-07T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Neuronetics posts May 2024 investor presentation to website; no specific financials provided","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Filed under Item 7.01 Regulation FD Disclosure on May 7, 2024.","Presentation posted at http://ir.neuronetics.com; content not summarized in filing.","No supplemental financial or operating data included in the 8-K text or exhibits."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":98118863.87704918,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":240418,"accession_number":"0001193125-24-080551","cik":1227636,"company_name":"Neuronetics, Inc.","ticker":"STIM","form_type":"8-K","filed_at":"2024-03-28T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Neuronetics reduces board to five directors; three incumbents depart","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board size cut from 8 to 5 effective after 2024 annual meeting.","Directors Bakewell, Capper, and Jaeger will not stand for reelection.","Decision based on analysis of similar companies and stockholder feedback.","Departures not due to any disagreement with company operations or policies.","Their board and committee service ends at the conclusion of the 2024 annual meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":98118863.87704918,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":240417,"accession_number":"0001193125-24-076600","cik":1227636,"company_name":"Neuronetics, Inc.","ticker":"STIM","form_type":"8-K","filed_at":"2024-03-25T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Neuronetics gets FDA clearance for NeuroStar as first-line adjunct for adolescent MDD (ages 15-21)","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA cleared NeuroStar Advanced Therapy as first-line adjunct treatment for major depressive disorder in adolescents aged 15-21.","Supplemental information posted to Neuronetics IR website on March 25, 2024.","Expands NeuroStar's indicated population beyond adults to include adolescents with MDD.","No financial details, revenue guidance, or commercial launch timeline were disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":98118863.87704918,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":240416,"accession_number":"0001193125-24-060703","cik":1227636,"company_name":"Neuronetics, Inc.","ticker":"STIM","form_type":"8-K","filed_at":"2024-03-06T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Neuronetics approves annual cash incentive awards: CEO $660,800, two EVPs $226,341 and $206,747","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CEO Keith J. Sullivan receives $660,800 annual cash incentive award, approved by Board on March 1, 2024.","EVP/CFO Stephen Furlong receives $226,341; EVP/GC Andrew Macan receives $206,747.","Awards are for annual incentive compensation; payment on or about March 7, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":98118863.87704918,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":240415,"accession_number":"0001558370-24-002411","cik":1227636,"company_name":"Neuronetics, Inc.","ticker":"STIM","form_type":"8-K","filed_at":"2024-03-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Neuronetics Q4 revenue up 12% to $20.3M; net loss narrows to $5.4M; first positive cash flow","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2023 revenue $20.3M (+12% YoY); full-year revenue $71.3M (+9% YoY).","Q4 net loss $(5.4)M ($(0.19)/share) vs $(8.3)M loss a year ago; first-ever positive cash flow of $1.5M.","U.S. treatment session revenue up 20% in Q4 to $14.9M; local consumable treatment session revenue up >33%.","Full-year 2024 revenue guidance $78M-$80M; Q1 2024 guidance $16.7M-$17.7M.","Launched Better Me Guarantee Provider pilot with ~100 sites; insurers reduce TMS eligibility to 2 medication failures."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":98118863.87704918,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":240414,"accession_number":"0001558370-24-002410","cik":1227636,"company_name":"Neuronetics, Inc.","ticker":"STIM","form_type":"8-K","filed_at":"2024-03-05T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Neuronetics posts investor presentation; filing contains no specific financial updates","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Investor presentation and supplemental financial/operating info posted to ir.neuronetics.com.","Filing under Item 7.01; no new financial figures or material events disclosed.","Presentation may include business highlights and forward-looking statements."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":98118863.87704918,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}